Análise opcional do produto
Com a sua autorização, usamos análises limitadas e respeitadoras da privacidade para perceber que percursos de investigação funcionam. Não usamos rastreadores publicitários nem gravação de sessões. Pode alterar esta escolha nas Preferências. Leia a Política de Privacidade.
The Cooper Companies, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $10.5B | |
|---|---|---|
| P/E (forward) | 11.3x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | Trend |
| Revenue | $2.92B | $3.31B | $3.59B | $3.90B | $4.09B | +8.8% |
| Gross profit | $1.96B | $2.14B | $2.36B | $2.60B | $2.68B | +8.2% |
| Operating income | $505.8M | $507.6M | $533.1M | $705.7M | $682.9M | +7.8% |
| Net income | $2.94B | $385.8M | $294.2M | $392.3M | $374.9M | -40.3% |
| EPS (diluted) | $14.79 | $1.94 | $1.48 | $1.96 | $1.87 | -40.4% |
| EBITDA | $823.9M | $878.7M | $885.9M | $1.07B | $1.05B | +6.3% |
| R&D | $92.7M | $110.3M | $137.4M | $155.1M | $172.2M | +16.7% |
| SG&A | $1.21B | $1.34B | $1.50B | $1.53B | $1.63B | +7.7% |
Recent company headlines from major financial publishers.
The Base case envisions steady compounding driven by ongoing conversion to premium daily disposable contact lenses, defensive gross margins, and gradual deleveraging. Performance tracks toward Fair value of $78.48, supported by stable replacement demand across optometry networks. The thesis would be challenged if European revenue decelerates or if surgical segment margins fail to recover.
The Bull case models accelerated market share gains in specialty silicone hydrogel daily lenses across Europe and Asia, accompanied by operational integration in Cooper Surgical that lifts segment margins. This outcome delivers Potential value of $92.70 as valuation multiples expand. Slower adoption of daily modalities would disconfirm this trajectory.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.7% | $96.5 | $103 | $111 | $122 | $136 |
| 7.7% | $82.6 | $86.6 | $91.5 | $97.5 | $105 |
| 8.7% | $72.7 | $75.3 | $78.5 | $82.2 | $86.7 |
| 9.7% | $65.1 | $67.0 | $69.2 | $71.7 | $74.6 |
| 10.7% | $59.2 | $60.6 | $62.1 | $63.9 | $65.9 |
Upcoming earnings date and setup when available.
A classificação que a edição de pesquisa publicada em cada mês trazia. Uma classificação compara o preço na data da análise com o valor justo; não é um registro de se a avaliação se confirmou.
| Ano | jan. | fev. | mar. | abr. | mai. | jun. | jul. | ago. | set. | out. | nov. | dez. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
